DBVT
DBV Technologies S.A.
NASDAQ · Healthcare · Biotechnology · FR
$13.47
−1.68%Jul 30, 2026, 21:40 UTC
DBV Technologies sold approximately $50 million of American Depositary Shares through its At-The-Market program on Nasdaq to RA Capital Management, with Citizens JMP Securities acting as sales agent.
Source:Jul 17, 2026, 21:00 UTC
DBV Technologies filed a prospectus supplement to refresh its at-the-market offering program for up to $150 million of American Depositary Shares.
Source:Jun 29, 2026, 20:00 UTC
DBV Technologies is preparing a Biologics License Application submission to the FDA for the VIASKIN Peanut Patch in children aged 4-7 years, with submission anticipated in Q3 2026.
Source:Jun 2, 2026, 23:40 UTC
DBV Technologies screened the first participant in the THRIVE Phase 2 study of the VIASKIN Peanut Patch for infants with peanut allergy.
Source: